Gogate A, et al. - Authors reviewed published articles focusing on metastatic breast cancer therapy to analyze the cost-effectiveness of therapies for metastatic breast cancer. They used the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist to assess the reporting quality of the included articles. They observed a moderate quality of articles. Findings revealed a gap in the literature as only three of the reviewed articles considered chemotherapies rather than treatments targeting either human epidermal growth factor receptor 2 (HER2) or hormone receptors, indicating moderate overall quality of the studies.